RE: NHS/NICE news due....19 Sep 2025 10:26
This was from March 27th 2025:
Gino Miele, CEO of genedrive plc, commented: "Thousands of people experience adverse reactions to drugs every year, with medicines being ineffective, or leading to unintended side effects or fatality. This costs the NHS £2.2 billion per year in England alone and it has been estimated that application of PGx could avoid this in approximately 39% of individuals, therefore saving £860 million per year. It is estimated that the value to the NHS of interventional CYP2C19 testing alone if implemented nationally is £160 million per year, equating to one-third of the total savings offered recently by the announcement of the abolishment of NHS England and the accompanying loss of 9,000 jobs. Having expanded our UK sales team, our international commercialisation partners and distribution network we are now seeing clear signs of commercial traction, where following significant preceding phases several sites are becoming routine clinical users, presenting a recurring source of revenue to the company. We are confident that this will continue to grow both in our domestic and international markets, with routine clinical use and growing revenue and pipeline opportunities evidencing clinical need and market fit for our novel products. The UK NHS has a huge opportunity to lead the way in precision medicine and indeed, organisations such as NHS Scotland have approached this in an integrated, forward thinking entrepreneurial manner with the pending deployment of MT-RNR1 and CYP2C19 testing at national scale. I am proud that our company is a key part of this and confident about our future commercial prospects in our markets."
.............................
I was waiting for NHS England to announce this being rolled out nationally. Also in the share price movement RNS:
"Furthermore, whilst the Company is aware of the completion of the NHSE CYP2C19 pilot assessing logistics of deploying as a service at scale via laboratory or point of care, and what, based on interim assessment it anticipates to be a positive outcome supporting the role and impact of rapid CYP2C19 genetic testing in stroke patients, it has not yet been made aware of a publication date by NHSE and cannot confirm the dates reportedly conveyed in the communication."
Also Gino Miele said should the conclusion of this should be around about now just after 20:30 on June 27th:
https://www.youtube.com/watch?v=MrfHKoBtmPM
That is main reason why I held thinking it was coming out within a week, not nearly 3 months and no news.
Sign In
Follow the stocks
